Translational Application of DNA Methylation Biomarkers in Malignant Tumors

Liu Jie,Tang Futian,Li Yuming
DOI: https://doi.org/10.12287/j.issn.2096-8965.20210302
2021-01-01
Abstract:Extensive genetic changes as well as related gene function and activity disorders occur in the development of malignant tumors. DNA methylation in epigenetics is one of the best-characterized epigenetic modifications. It affects gene expression and genome stability, having an important impact on the development of malignant tumors. Most of these epigenetic changes occur in the early stages of malignant tumors and are widespread in the entire malignant tumor. DNA methylation biomarkers are important methods for early tumor diagnosis,prognosis and treatment detection. Cancer-related DNA methylation changes can be detected in blood, feces, urine and other biological samples. It is a non-invasive, rapid and reproducible alternative to tissue biopsy. DNA methylation is a simple, economical and highly specific malignant tumor detection method that can be applied to population screening. Although it faces many challenges, DNA methylation biomarkers have unique advantages, having the prospect of clinical translational application and value. This article reviews the characteristics of DNA methylation, the mechanism of action as well as the latest research progress in early diagnosis, clinical treatment effects,and prognosis determination in bladder cancer, breast cancer, colorectal cancer and other malignant tumors, discussing the problems and prospects of clinical translation.
What problem does this paper attempt to address?